An interventional study of Bioblation in Prostate Cancer, Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic Hyperplasia, sponsored by Benha University. Recruiting at 1 site in Egypt. Open to male participants aged 18 Months and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Benha University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Prostatic Neoplasms with a site in Egypt — 7 open to participants now, 9 under way, none of them phase 3. Prostatic Neoplasms · Egypt.
Among the 25 studies in Prostatic Neoplasms with a site in Egypt, this one is the 17th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2026, is one of 10 with no phase, and was the 23rd registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →7 of the 25 studies in Prostatic Neoplasms with a site in Egypt are open now. Recruiting first, the newest first:
Nazmy Edward Seif · Sites in Egypt
Ages 40–80 · Men only
Menoufia University · Sites in Egypt
Men only
Ain Shams University · Sites in Egypt
Ages 18+ · Men only
Assiut University · Sites in Egypt
Men only
Sohag University · Sites in Egypt
Ages 40+ · Men only
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Months and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 1 · Phase 4 2
First in 2013; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 80 across the 18 interventional studies, 120 across the 7 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 25 have an industry lead sponsor. The 10 most frequent:
Benha University is the lead sponsor of 364 studies on the registry; 67 are open to participants now.
Benha University has 1 study filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Prostatic Neoplasms with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06408597Nazmy Edward SeifMannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystectomy | 2026-11 |
| NCT07626151Nazmy Edward SeifElectric Cardiometry-Guided Standard Versus Restricted Fluid Therapy In Robotic Prostaectomy | 2026-12 |
| NCT07526675Benha UniversityConcomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer | 2027-04-20 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies in Prostatic Neoplasms with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective study aims to validate the clinical outcomes of performing a concomitant trans-perineal prostate biopsy and laser ablation (termed "Bioblation") during a single session. The intervention is designed for symptomatic patients presenting with lower urinary tract symptoms (LUTS) who are highly suspected to have low to favorable intermediate-risk prostate cancer. By combining diagnosis and targeted treatment under local anesthesia, this approach seeks to facilitate early relief of severe symptoms and a rapid return to daily activities. Ultimately, the study evaluates whether this combined procedure decreases the patient's exposure to multiple, temporally separated interventions without compromising oncological safety or efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with severe Lower Urinary Tract Symptoms (LUTS) meeting the following parameters:
Patients most probably having low to favorable intermediate-risk prostate cancer, defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with severe lower urinary tract symptoms (LUTS) and suspected low to favorable intermediate-risk prostate cancer undergoing concomitant trans-perineal prostate biopsy and laser ablation in a single session
Procedure: Bioblation
The procedure is performed under local anesthesia and a prostatic nerve block. Under real-time transrectal ultrasound (TRUS) visualization, four biopsy cores are taken transperineally from each suspected focal lesion, alongside systematic biopsies of the transitional zones. Immediately following the biopsy, 18G Chipa needles are inserted transperineally to pass 300-micron laser fibers to the target site. Using the Elesta system, 7W of laser energy is delivered via MRI-guided cognitive fusion to induce thermal coagulative necrosis of the tumor.
Also known as: Elesta laser system
Change in International Prostate Symptom Score (IPSS)
The IPSS is a validated questionnaire used to assess the severity of lower urinary tract symptoms (LUTS). The total score ranges from 0 to 35, where 0-7 indicates mildly symptomatic, 8-19 moderately symptomatic, and 20-35 severely symptomatic. A decrease in the score indicates an improvement in symptoms.
Time frame: Baseline, 1, 3, 6, 9, and 12 months post-procedure
Change in Maximum Urinary Flow Rate (Q-max)
Maximum urinary flow rate will be measured using uroflowmetry to assess functional improvement in urination. It is measured in milliliters per second (mL/sec). A higher value indicates better urinary flow and less obstruction.
Time frame: Baseline, 1, 3, 6, 9, and 12 months post-procedure
Change in Post-Void Residual (PVR) Urine Volume
PVR will be measured via ultrasound to determine the volume of urine remaining in the bladder immediately after urination. It is measured in milliliters (mL) or cubic centimeters (cc). A lower volume indicates better bladder emptying.
Time frame: Baseline, 1, 3, 6, 9, and 12 months post-procedure
Change in Prostate Volume
Total prostate gland volume will be assessed using transrectal ultrasound (TRUS) or multiparametric MRI. It is measured in cubic centimeters (cc) or milliliters (mL). A decrease in volume indicates a reduction in gland size following the ablation procedure.
Time frame: Baseline, 1, 3, 6, 9, and 12 months post-procedure
Change in Total Serum Prostate-Specific Antigen (PSA)
Measurement of total serum PSA levels (in ng/mL) to monitor oncological control, disease status, and therapeutic response following the focal ablation of the suspected prostate lesions.
Time frame: Baseline, 1, 3, 6, 9, and 12 months post-procedure
Incidence of Procedure-Related Complications
The occurrence, type, and severity of post-operative adverse events (such as hematuria, acute urinary retention, fever, or signs of infection) will be recorded to evaluate the safety profile of the concomitant biopsy and ablation procedure.
Time frame: Up to 12 months post-procedure
Plan to share: Undecided
Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.
Of 1,100 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 12 months is below that.
Counting every sponsor, half of 1,157 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Apr 2026 → Apr 2027 and completion Apr 2026 → Apr 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.